In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Health claims

This article was originally published in The Tan Sheet

Executive Summary

D.C. federal appeals court's mandate for the implementation of the Pearson v. Shalala health claims decision issued to FDA April 20. The court ruled Jan. 15 that FDA's approach to regulating health claims for dietary supplements is unconstitutional and ordered the agency to clarify its significant scientific agreement standard and reconsider four claims ("The Tan Sheet" Jan. 25, p. 3). An agency petition for rehearing the case was denied April 2. FDA has until July 1 to request a Supreme Court review, after which the appeals court decision is final. Five House Republicans request FDA "spare the taxpayers the cost of further legal proceedings in the matter" in an April 19 letter to the agency. The letter is signed by Reps. Ron Paul (Tex.), Dan Burton (Ind.), Helen Chenoweth (Idaho), John Hostetler (Ind.), and Bob Stump (Ariz.). The group made a similar request prior to FDA's request for a rehearing

You may also be interested in...

People In Brief

Perrigo promotes in pricing, planning

In Brief

Combe sells most of its OTC brands

Supplement GMP Warning Letters Make Modest Debut In 2010

Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts